Triumph Capital Management’s Eledon Pharmaceuticals ELDN Stock Holding History

Triumph Capital Management’s Portfolio ELDN Stock Details ELDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.2M	Buy	+303,443	New	+$1.1M	0.22%	110

Other funds holding ELDN

Prodigy Asset Management Omaha, Nebraska $332M AUM 10.57% 1-Year Est. Return

Wealth Enhancement Advisory Services

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Howard Financial Services Dallas, Texas $1B AUM 20.02% 1-Year Est. Return

Relyea Zuckerberg Hanson Stamford, Connecticut $1.2B AUM 28.45% 1-Year Est. Return

Revolve Wealth Partners Hackensack, New Jersey $965M AUM 22.88% 1-Year Est. Return

GK Wealth Management Reno, Nevada $190M AUM 66.42% 1-Year Est. Return

Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return

Everhart Financial Group Dublin, Ohio $1.56B AUM 34.29% 1-Year Est. Return

Farmers & Merchants Investments Inc Lincoln, Nebraska $4.13B AUM 32.58% 1-Year Est. Return

SOA Wealth Advisors New York $595M AUM 25.98% 1-Year Est. Return

Triumph Capital Management's ELDN Position: Q2 2026 in Review

Triumph Capital Management opened a new position in Eledon Pharmaceuticals (ELDN) in Q2 2026: 303,443 shares worth $1.2M. The stake represents 0.22% of the portfolio and ranks #110 among its holdings.

19 funds tracked by Wall St. Rank hold ELDN as of Q2 2026.

Triumph Capital Management held 303,443 shares of Eledon Pharmaceuticals worth $1.2M as of Q2 2026.
Eledon Pharmaceuticals was a new Triumph Capital Management position in Q2 2026.
Eledon Pharmaceuticals made up 0.22% of Triumph Capital Management's portfolio in Q2 2026, its #110 holding.
19 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q2 2026.

Based on Triumph Capital Management's 13F filing for Q2 2026, filed 21 Jul 2026.